Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05254743




Registration number
NCT05254743
Ethics application status
Date submitted
15/02/2022
Date registered
24/02/2022
Date last updated
13/05/2024

Titles & IDs
Public title
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Scientific title
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Secondary ID [1] 0 0
J2N-OX-JZNU
Secondary ID [2] 0 0
18281
Universal Trial Number (UTN)
Trial acronym
BRUIN-CLL-314
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Leukemia, Lymphocytic 0 0
Leukemia, B-cell 0 0
Small Lymphocytic Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Pirtobrutinib
Treatment: Drugs - Ibrutinib

Experimental: Pirtobrutinib - Administered orally.

Active Comparator: Ibrutinib - Administered orally.


Treatment: Drugs: Pirtobrutinib
Administered orally.

Treatment: Drugs: Ibrutinib
Administered orally.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR)
Timepoint [1] 0 0
Baseline to best overall response at or before the initiation of subsequent anti-cancer therapy (if any) (approximately 3 years and 5 months)
Secondary outcome [1] 0 0
Event-Free Survival (EFS)
Timepoint [1] 0 0
Randomization to first occurrence of treatment discontinuation due to adverse event/toxicity, treatment-emergent atrial fibrillation or atrial flutter of any grade, progressive disease (PD) or death (approximately 4 years)
Secondary outcome [2] 0 0
Progression-Free Survival (PFS)
Timepoint [2] 0 0
Randomization to PD (per iwCLL 2018 criteria) or death from any cause (approximately 5 years 8 months)
Secondary outcome [3] 0 0
Duration of Response (DOR)
Timepoint [3] 0 0
Time from the date of the first documented response of CR, CRi, nPR or PR to the earlier of documentation of definitive PD (per iwCLL 2018 criteria) or death from any cause (approximately 2 years)
Secondary outcome [4] 0 0
Overall Survival (OS)
Timepoint [4] 0 0
Randomization to death from any cause (approximately 6 years)
Secondary outcome [5] 0 0
Time to Next Treatment (TTNT)
Timepoint [5] 0 0
Randomization to initiation of the next systemic anticancer therapy for CLL/SLL or death from any cause, whichever occurs first (approximately 6 years)
Secondary outcome [6] 0 0
Time to Worsening (TTW) of CLL/SLL Related Symptoms
Timepoint [6] 0 0
Randomization to time to worsening symptoms (approximately 6 years)

Eligibility
Key inclusion criteria
- Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Adequate organ function

- Platelets greater than or equal to (=)50 x 10?/liter (L) or =30 x 10?/L in
participants with documented bone marrow involvement considered to impair
hematopoiesis,

- Hemoglobin =8 grams/deciliter (g/dL) or =6 g/dL in participants with documented
bone marrow involvement considered to impair hematopoiesis

- Absolute neutrophil count =0.75 x 10?/L or =0.50 × 10?/L in participants with
documented bone marrow involvement considered to impair hematopoiesis

- Kidney function: Estimated creatinine clearance =30 milliliters per minute
(mL/min)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL),
prolymphocytic leukemia, or Hodgkin's lymphoma at any time preceding enrollment

- Known or suspected central nervous system (CNS) involvement

- A significant history of renal, neurologic, psychiatric, endocrine, metabolic or
immunologic disease

- Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA],
idiopathic thrombocytopenic purpura [ITP])

- Significant cardiovascular disease including ejection fraction < 40% and any grade
ongoing atrial fibrillation or atrial flutter

- Hepatitis B or hepatitis C testing indicating active/ongoing infection, based on
Screening laboratory tests

- Active cytomegalovirus (CMV) infection

- Active uncontrolled systemic bacterial, viral, or fungal infection

- Known human immunodeficiency virus (HIV) infection, regardless of cluster of
differentiation 4 (CD4) count

- Clinically significant active malabsorption syndrome or other condition likely to
affect GI absorption of the oral-administered study treatments

- Ongoing inflammatory bowel disease

- Prior exposure to BTK inhibitor (covalent or noncovalent)

- Concurrent use of investigational agent or anticancer therapy except hormonal therapy

- Participants requiring therapeutic anticoagulation with warfarin or another Vitamin K
antagonist

- Use of = 20 mg prednisone daily or equivalent dose of steroid at the time of first
dose of study drug

- Vaccination with a live vaccine within 28 days prior to randomization

- Participants receiving chronic therapy with a strong cytochrome P450 (CYP)3A inhibitor
(except posaconazole and voriconazole) which cannot be stopped within 3-5 half lives
of the CYP3A inhibitor therapy prior to start of study drug treatment

- Participants with known hypersensitivity, including anaphylaxis, to any component or
excipient of pirtobrutinib or ibrutinib

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/07/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2028
Actual
Sample size
Target
650
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Sunshine Hospital - St Albans
Recruitment hospital [2] 0 0
One Clinical Research - Nedlands
Recruitment hospital [3] 0 0
The Perth Blood Institute - West Perth
Recruitment postcode(s) [1] 0 0
3021 - St Albans
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Montana
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Ciudad Autónoma De Buenos Aire
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Autonoma Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Santa Fe
Country [24] 0 0
Austria
State/province [24] 0 0
Oberösterreich
Country [25] 0 0
Austria
State/province [25] 0 0
Vienna
Country [26] 0 0
Belgium
State/province [26] 0 0
Oost-Vlaanderen
Country [27] 0 0
Belgium
State/province [27] 0 0
West Flanders
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Brazil
State/province [29] 0 0
Paraná
Country [30] 0 0
Brazil
State/province [30] 0 0
Rio Grande Do Sul
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
São Paulo
Country [33] 0 0
Brazil
State/province [33] 0 0
Cascavel
Country [34] 0 0
Canada
State/province [34] 0 0
Manitoba
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Canada
State/province [36] 0 0
Québec
Country [37] 0 0
Chile
State/province [37] 0 0
IX Región
Country [38] 0 0
Chile
State/province [38] 0 0
Región Metropolitana
Country [39] 0 0
Chile
State/province [39] 0 0
Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
Valparaíso
Country [41] 0 0
China
State/province [41] 0 0
Anhui
Country [42] 0 0
China
State/province [42] 0 0
Guangdong
Country [43] 0 0
China
State/province [43] 0 0
Guangxi
Country [44] 0 0
China
State/province [44] 0 0
Hubei
Country [45] 0 0
China
State/province [45] 0 0
Hunan
Country [46] 0 0
China
State/province [46] 0 0
Jiangxi
Country [47] 0 0
China
State/province [47] 0 0
Shanghai
Country [48] 0 0
China
State/province [48] 0 0
Tianjin
Country [49] 0 0
China
State/province [49] 0 0
Xinjiang
Country [50] 0 0
China
State/province [50] 0 0
Zhejiang
Country [51] 0 0
China
State/province [51] 0 0
Haikou
Country [52] 0 0
China
State/province [52] 0 0
Hangzhou
Country [53] 0 0
China
State/province [53] 0 0
Wuhan
Country [54] 0 0
Czechia
State/province [54] 0 0
Brno
Country [55] 0 0
Czechia
State/province [55] 0 0
Hradec Kralove
Country [56] 0 0
Czechia
State/province [56] 0 0
Ostrava-Poruba
Country [57] 0 0
Czechia
State/province [57] 0 0
Plzen - Lochotin
Country [58] 0 0
Czechia
State/province [58] 0 0
Praha 10
Country [59] 0 0
Czechia
State/province [59] 0 0
Praha 2
Country [60] 0 0
France
State/province [60] 0 0
Cedex 13
Country [61] 0 0
France
State/province [61] 0 0
Cedex 1
Country [62] 0 0
France
State/province [62] 0 0
Cedex 9
Country [63] 0 0
France
State/province [63] 0 0
Cedex
Country [64] 0 0
France
State/province [64] 0 0
Nice Cedex 2
Country [65] 0 0
France
State/province [65] 0 0
Tours Cedex 9
Country [66] 0 0
France
State/province [66] 0 0
La Roche sur Yon
Country [67] 0 0
France
State/province [67] 0 0
Le Mans
Country [68] 0 0
France
State/province [68] 0 0
Limoges
Country [69] 0 0
France
State/province [69] 0 0
Rouen Cedex
Country [70] 0 0
Germany
State/province [70] 0 0
Baden
Country [71] 0 0
Germany
State/province [71] 0 0
Köln
Country [72] 0 0
Germany
State/province [72] 0 0
Nordrhein Westfalen
Country [73] 0 0
Germany
State/province [73] 0 0
Sachsen Anhalt
Country [74] 0 0
Germany
State/province [74] 0 0
Sachsen
Country [75] 0 0
Hungary
State/province [75] 0 0
Debrecen
Country [76] 0 0
Hungary
State/province [76] 0 0
Szombathely
Country [77] 0 0
Israel
State/province [77] 0 0
Jerusalem
Country [78] 0 0
Israel
State/province [78] 0 0
Petach-Tikva
Country [79] 0 0
Israel
State/province [79] 0 0
Ramat Gan
Country [80] 0 0
Israel
State/province [80] 0 0
Tel Aviv
Country [81] 0 0
Italy
State/province [81] 0 0
Forlì-Cesena
Country [82] 0 0
Italy
State/province [82] 0 0
Otago
Country [83] 0 0
Italy
State/province [83] 0 0
Torino
Country [84] 0 0
Italy
State/province [84] 0 0
Alessandria
Country [85] 0 0
Italy
State/province [85] 0 0
Bologna
Country [86] 0 0
Italy
State/province [86] 0 0
Milano
Country [87] 0 0
Italy
State/province [87] 0 0
Reggio Emilia
Country [88] 0 0
Italy
State/province [88] 0 0
Verona
Country [89] 0 0
Japan
State/province [89] 0 0
Kanagawa
Country [90] 0 0
Japan
State/province [90] 0 0
Kumamoto
Country [91] 0 0
Japan
State/province [91] 0 0
Yamagata
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
Seoul, Korea
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Seoul
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Busan
Country [95] 0 0
New Zealand
State/province [95] 0 0
Wellington
Country [96] 0 0
New Zealand
State/province [96] 0 0
Dunedin
Country [97] 0 0
New Zealand
State/province [97] 0 0
Hamilton
Country [98] 0 0
New Zealand
State/province [98] 0 0
Otahuhu
Country [99] 0 0
Poland
State/province [99] 0 0
Pomorskie
Country [100] 0 0
Poland
State/province [100] 0 0
Poznan
Country [101] 0 0
Poland
State/province [101] 0 0
Biala Podlaska
Country [102] 0 0
Poland
State/province [102] 0 0
Bydgoszcz
Country [103] 0 0
Poland
State/province [103] 0 0
Katowice
Country [104] 0 0
Poland
State/province [104] 0 0
Krakow
Country [105] 0 0
Poland
State/province [105] 0 0
Lublin
Country [106] 0 0
Poland
State/province [106] 0 0
Opole
Country [107] 0 0
Poland
State/province [107] 0 0
Wroclaw
Country [108] 0 0
Spain
State/province [108] 0 0
Cataluna
Country [109] 0 0
Spain
State/province [109] 0 0
Catalunya [Cataluña]
Country [110] 0 0
Spain
State/province [110] 0 0
Cataluña
Country [111] 0 0
Spain
State/province [111] 0 0
Madrid, Comunidad De
Country [112] 0 0
Spain
State/province [112] 0 0
Malaga
Country [113] 0 0
Spain
State/province [113] 0 0
Navarra
Country [114] 0 0
Spain
State/province [114] 0 0
Barcelona
Country [115] 0 0
Spain
State/province [115] 0 0
L'Hospitalet de Llobregat
Country [116] 0 0
Spain
State/province [116] 0 0
Las Palmas de Gran Canaria
Country [117] 0 0
Spain
State/province [117] 0 0
Madrid
Country [118] 0 0
Spain
State/province [118] 0 0
Santander
Country [119] 0 0
Spain
State/province [119] 0 0
Sevilla
Country [120] 0 0
Taiwan
State/province [120] 0 0
Chiayi Hsien
Country [121] 0 0
Taiwan
State/province [121] 0 0
Changhua
Country [122] 0 0
Taiwan
State/province [122] 0 0
Tainan
Country [123] 0 0
Taiwan
State/province [123] 0 0
Taipei
Country [124] 0 0
Turkey
State/province [124] 0 0
Ankara
Country [125] 0 0
Turkey
State/province [125] 0 0
Izmir
Country [126] 0 0
Turkey
State/province [126] 0 0
Yenimahalle
Country [127] 0 0
Turkey
State/province [127] 0 0
Istanbul
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Bristol, City Of
Country [129] 0 0
United Kingdom
State/province [129] 0 0
East Riding Of Yorkshire
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Leicestershire
Country [131] 0 0
United Kingdom
State/province [131] 0 0
London, City Of
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Loxo Oncology, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305)
to ibrutinib in participants with CLL/SLL. Participants may or may not have already had
treatment for their cancer. Participation could last up to six years.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05254743
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Address 0 0
Country 0 0
Phone 0 0
1-317-615-4559
Fax 0 0
Email 0 0
ClinicalTrials.gov@lilly.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05254743